ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years. Here's what you need to know about the ...

Plasma cell leukemia (PCL) is a rare disease that may ... lenalidomide and transplant-based regimens will probably improve treatment outcome. There is insufficient information to support ...

Literature about PPCL treatment is limited, sometimes conflicting, and often based on case reports or small retrospective series that frequently include both younger and elderly patients or secondary ...

An international clinical trial co-led by Roswell Park Comprehensive Cancer Center has demonstrated that the investigational ...

In addition, the researchers discovered that plasma cells secreting anti-CD19 bispecific antibodies elicited antitumor activity, as demonstrated with acute lymphoblastic leukemia patient-derived ...

Researchers show for the first time that engineered human plasma B cells ... leukemia (B-ALL). Blinatumomab is a bispecific antibody that received FDA approval in 2014 for the treatment of ...

Steroids enhance the efficacy of my cancer chemo treatment, but its long term ... years in cancer remission of multiple myeloma/plasma cell leukemia. He has been sober for 32 years.

Hairy-cell leukemia (HCL) is a rare ... a remitting–relapsing pattern of response to sequential treatments, and an almost normal life expectancy with current therapies. The BRAF V600E kinase ...

Cancer is an umbrella term for abnormal excess growth that can occur in any part of the body. Leukemia is the cancer of blood, which means there is rapid growth of abnormal blood cells. This ...

Her treatment consisted of rhubarb pills and ... levels (≥2 times the upper level of normal), and evidence of plasma cell leukemia (defined as ≥5% circulating clonal plasma cells on peripheral ...

and plasma cell leukemia (6% vs 0%). Extramedullary disease was also more common (26% vs 13%), and 14% had prior BCMA-targeted therapy. Among infused patients, 54% would not have met CARTITUDE-1 ...